BioSpace News Archive

CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to five new employees as equity inducement awards outside of the Company’s Amended and Restated 2017 Equity Incentive Plan and material to the employees’ acceptance of employment with the company.

Research from a large international effort shows that 20% of children with cancer who are infected with SARS-CoV-2 develop severe infections.

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), and Bolt Biotherapeutics, Inc. (“Bolt”) (Nasdaq: BOLT), today announced a drug research and development collaboration to develop three new anti-cancer therapeutic immune-stimulating antibody conjugate (ISAC) candidates.

Laekna Therapeutics announced that the Center for Drug Evaluation, the National Medical Products Administration of China has approved the Investigational New Drug application of its Category 1 new drug candidate afuresertib in combination with anti-estrogen receptor drug fulvestrant in the Phase Ib/III clinical trial of patients with locally advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.

MediCardia Health Inc., today announced the appointment of Glenn Recker as Chief Product Officer.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that it has notified The Texas A&M University System (“TAMUS”) of its exercise of the option to an exclusive license for the global development and commercialization of highly potent main protease (MPro) inhibitors against SARS-CoV-2 and all current and emerging variants of concern (VOCs).

The event will be hosted live on the Cybeats YouTube2 channel on September 9th at 1pm EDT.

Inari Medical, Inc., a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced that its management team will present at the following upcoming investor conferences:

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the fiscal quarter ended June 30, 2021, and provided business updates.

Sight Sciences, Inc. (Nasdaq: SGHT), today announced plans to participate in the upcoming virtual Morgan Stanley Global Healthcare Conference.